MGC Pharma secures European CPNP approval for skincare products

MGC Pharmaceuticals has secured approval from the European Cosmetics Products Notification Portal (CPNP) for registration of its three cannabidiol (CBD) based dermatological skincare products.

The three products were developed to provide relief from skin conditions such as acne, psoriasis, and seborrhoea. Prior to seeking approval, the company completed safety assessments and human skin patch testing.

MGC Pharmaceuticals' co-founder and managing director Nativ Segev said: “Receiving European CPNP approval for our new dermatological products is another crucial step forward on the path to generating significant revenues from our MGC Derma skincare product range, with these new dermatology tested products to be used for the relief of psoriasis, acne, and seborrhoea skin conditions.  

"This is potentially a huge global market that we intend to start selling into this year.

“With this crucial European approval now granted for MGC Derma, we are now commencing the clinical tests to validate the efficacy of the products.

"Not only will these tests build on the safety evidence we already have for the products to start commercial sales, but they will help us shape a strong efficacy-based consumer marketing programme that communicates the benefits of our cannabidiol dermatological products for skincare.”

The company will commence clinical tests on human volunteers this month at Slovenian dermatology clinic, to determine the efficacy of the products.

The clinical tests will evaluate the products for the relief of indications such as redness, dryness, and flakey, acneic, and oily skin in human volunteers over a period of three months.

The new products expand the company's current line of CBD-based cosmetics products under MGC Derma brand. Post manufacturing, the new products will be available for purchase on the MGC Derma online shop as well as at select European retail outlets and pharmacy chains.